Tonix Pharmaceuticals Hol...

20.38
4.10 (25.18%)
At close: Mar 18, 2025, 3:59 PM
18.08
-11.27%
Pre-market: Mar 19, 2025, 05:48 AM EDT
25.18%
Bid 17.88
Market Cap 113.93M
Revenue (ttm) 1.02M
Net Income (ttm) -12.17M
EPS (ttm) -8039
PE Ratio (ttm) n/a
Forward PE -0.02
Analyst Strong Buy
Ask 18.29
Volume 2,503,427
Avg. Volume (20D) 1,600,886
Open 16.00
Previous Close 16.28
Day's Range 15.51 - 21.70
52-Week Range 6.76 - 1184.00
Beta 2.24

About TNXP

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...

Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2012
Employees 103
Stock Exchange NASDAQ
Ticker Symbol TNXP
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $1100, which is an increase of 5297.45% from the latest price.

Stock Forecasts

Earnings Surprise

Tonix Pharmaceuticals has released their quartely earnings on Mar 18, 2025:
  • Revenue of $2.58M misses estimates by $618K, with -31.68% YoY decline.
  • EPS of -9.77 exceeds estimates by 758.23, with 99.64% YoY growth.
  • Next Earnings Release

    Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on May 12, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +10.23%
    Tonix Pharmaceutical shares are trading higher aft... Unlock content with Pro Subscription
    1 month ago
    -54.47%
    Tonix Pharmaceuticals shares are trading lower after the company announced a 1-for-100 reverse stock split.